{"id":"W3167099310","doi":"10.1200/jco.2021.39.15_suppl.tps5087","title":"Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using <sup>177</sup>Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Enzalutamide; Clinical endpoint; Prostate cancer; Oncology; Hormonal therapy; Radionuclide therapy; Internal medicine; Androgen deprivation therapy; Cabazitaxel; Abiraterone acetate; Chemotherapy; Clinical trial; Cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002696081,0.001492621,0.00231465,0.0004966846,0.0005917303,0.0008927296,0.001167718,0.001338613,0.006058208],"category_scores_gemma":[0.001019127,0.000648052,0.001590519,0.0005424292,0.001410573,0.0009211132,0.0004505588,0.002966063,0.001230967],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001121621,"about_ca_system_score_gemma":0.00231115,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002541034,"about_ca_topic_score_gemma":0.002809214,"domain_scores_codex":[0.9991196,0.0004641534,0.00004157806,0.0001350224,0.00007375916,0.0001659757],"domain_scores_gemma":[0.9985431,0.0002722534,0.0002054902,0.0001766204,0.00008019333,0.0007223736],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7063954,0.1948083,0.00650692,0.0006352085,0.0009800375,0.0003207024,0.0003552954,0.002334633,0.05375692,0.0003018027,0.00140804,0.03219671],"study_design_scores_gemma":[0.1366061,0.8511666,0.005905168,0.00001082136,0.000264559,0.0001428534,0.00003411496,0.0005763302,0.004087966,0.0000702066,0.001119758,0.00001553109],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947666,0.0004771836,0.00037364,0.0001566525,0.00007833631,0.002494552,0.0005389928,0.00004645643,0.001067493],"genre_scores_gemma":[0.9895239,0.0006756862,0.001547896,0.0004378852,0.0002091929,0.003282542,0.001633019,0.0000384767,0.002651433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006058208,"threshold_uncertainty_score":0.02026677,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4126903825457351,"score_gpt":0.5696239092667471,"score_spread":0.156933526721012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}